Literature DB >> 1864347

Independent risk factors for cumulative recurrence rate after first spontaneous pneumothorax.

H L Lippert1, O Lund, S Blegvad, H V Larsen.   

Abstract

From 1975 until 1987, 122 patients without (Group I, mean age 34 yrs) and 20 with pre-existing lung disease (Group II, mean age 66 yrs) were treated for their first spontaneous pneumothorax. Mean follow-up was 5.2 yrs (max. 12.8 yrs). There were 32 chest X-ray verified recurrences, 72% occurring during the first 2 yrs. One, 5 and 10 yr cumulative recurrence freedoms +/- standard error in groups I and II combined were 85 +/- 3%, 75 +/- 4% and 69 +/- 5%, respectively. Using Cox regression analysis in groups I and II combined, pulmonary fibrosis, age greater than or equal to 60 yrs, and height/weight ratio were independent predictors of recurrence. Combinations of these risk factors identified four risk strata with 10 yr recurrence freedoms ranging from 83-0%. Independent predictors in group I alone were pulmonary fibrosis, age greater than or equal to 60 yrs, height/weight ratio, and nonsmoking, resulting in four risk strata with 10 yr recurrence freedoms ranging from 98-31%. Recurrences after first-time treated spontaneous pneumothorax showed a distinct time-related pattern and should accordingly be analysed as a time-related event. In both the total patient-population and in the group without pre-existing lung disease, independent predictors of recurrence were identified, which allowed the patients to be substratified into groups with widely different recurrence rates.

Entities:  

Mesh:

Year:  1991        PMID: 1864347

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  33 in total

1.  Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations.

Authors: 
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

2.  BTS guidelines for the management of spontaneous pneumothorax.

Authors:  M Henry; T Arnold; J Harvey
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

3.  Correlation of matrix metalloproteinase-2 and -9 expression with recurrences in primary spontaneous pneumothorax patients.

Authors:  Wen-Chin Chiu; Yi-Chen Lee; Yu-Han Su; Chee-Yin Chai; Stephen Chu-Sung Hu; Shyng-Shiou F Yuan; Shah-Hwa Chou
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

4.  Long-term effect of a thoracoscopic stapled bullectomy alone for preventing the recurrence of primary spontaneous pneumothorax.

Authors:  Kozo Nakanishi
Journal:  Surg Today       Date:  2009-06-28       Impact factor: 2.549

5.  Influence of old pulmonary tuberculosis on the management of secondary spontaneous pneumothorax in patients over the age of 70 years.

Authors:  Sang Cjeol Lee; Deok Heon Lee
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

6.  Postoperative predictors of ipsilateral and contralateral recurrence in patients with primary spontaneous pneumothorax.

Authors:  Ying-Yi Chen; Hsu-Kai Huang; Hung Chang; Shih-Chun Lee; Tsai-Wang Huang
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

7.  Recurrence of primary spontaneous pneumothorax.

Authors:  R T Sadikot; T Greene; K Meadows; A G Arnold
Journal:  Thorax       Date:  1997-09       Impact factor: 9.139

8.  Induction of heme oxygenase-1, biliverdin reductase and H-ferritin in lung macrophage in smokers with primary spontaneous pneumothorax: role of HIF-1alpha.

Authors:  Delphine Goven; Anne Boutten; Véronique Leçon-Malas; Joëlle Marchal-Sommé; Paul Soler; Jorge Boczkowski; Marcel Bonay
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

9.  Surgery for secondary spontaneous pneumothorax: risk factors for recurrence and morbidity.

Authors:  Mitsuhiro Isaka; Katsuyuki Asai; Norikazu Urabe
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-05-14

Review 10.  Chronic obstructive pulmonary disease * 11: fitness to fly with COPD.

Authors:  A O C Johnson
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.